Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [41] Clinical considerations of anticoagulation therapy for patients with atrial fibrillation
    Zhang, Shu
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2012, 13 (08): : 609 - 615
  • [42] Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting
    Han, Seol Young
    Palmeri, Sebastian T.
    Broderick, Samuel H.
    Hasselblad, Vic
    Rendall, Dave
    Stevens, Scott
    Tenaglia, Alan
    Velazquez, Eric
    Whellan, David
    Wagner, Galen
    Heitner, John F.
    JOURNAL OF ELECTROCARDIOLOGY, 2013, 46 (01) : 45 - 50
  • [43] Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Sherwood, Matthew W.
    Douketis, James D.
    Patel, Manesh R.
    Piccini, Jonathan P.
    Hellkamp, Anne S.
    Lokhnygina, Yuliya
    Spyropoulos, Alex C.
    Hankey, Graeme J.
    Singer, Daniel E.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    Califf, Robert M.
    Becker, Richard C.
    CIRCULATION, 2014, 129 (18) : 1850 - 1859
  • [44] Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation
    Hitaka, Yuka
    Ogawa, Masahiro
    Zhang, Bo
    Goto, Shunichiro
    Nagata, Yoshihisa
    Morii, Joji
    Imaizumi, Satoshi
    Yasuda, Tomoo
    Matsumoto, Naomichi
    Matsunaga, Akira
    Saku, Keijiro
    JOURNAL OF CARDIOLOGY, 2016, 68 (5-6) : 529 - 535
  • [45] Thromboembolic and haemorrhagic events in patients with atrial fibrillation: a prospective cohort study in UK primary and secondary care
    Robson, John
    Mathur, Rohini
    Priebe, Marian
    Ahmed, Zaheer
    Ayerbe, Luis
    BRITISH JOURNAL OF GENERAL PRACTICE, 2019, 69 (683) : E407 - E412
  • [46] Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2013, 21 (04) : 207 - 212
  • [47] Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    Lee, Hsin-Fu
    See, Lai-Chu
    Tu, Hui-Tzu
    Chao, Tze-Fan
    Yeh, Yung-Hsin
    Wu, Lung-Sheng
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Lip, Gregory Y. H.
    CHEST, 2019, 156 (03) : 529 - 543
  • [48] Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
    Ritchie, Leona A.
    Harrison, Stephanie L.
    Penson, Peter E.
    Akbari, Ashley
    Torabi, Fatemeh
    Hollinghurst, Joe
    Harris, Daniel
    Oke, Oluwakayode B.
    Akpan, Asangaedem
    Halcox, Julian P.
    Rodgers, Sarah E.
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2023, 73 (726) : E43 - E51
  • [49] Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
    Laliberte, Francois
    Cloutier, Michel
    Nelson, Winnie W.
    Coleman, Craig I.
    Pilon, Dominic
    Olson, William H.
    Damaraju, C. V.
    Schein, Jeffrey R.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (07) : 1317 - 1325
  • [50] Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation Results from the Dresden NOAC Registry
    Hecker, Judith
    Marten, Sandra
    Keller, Loretta
    Helmert, Sindy
    Michalski, Franziska
    Werth, Sebastian
    Sahin, Kurtulus
    Tittl, Luise
    Beyer-Westendorf, Jan
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (05) : 939 - 949